Sight Sciences Introduces the SION™ Surgical Instrument – The First Bladeless Device Used in Goniotomy
August 23, 2022 08:03 ET | Sight Sciences, Inc.
MENLO PARK, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to...
Straits Research Pvt Ltd
OTC Artificial Tears Market Size is projected to reach USD 6.79 Billion by 2030, growing at a CAGR of 5.10%: Straits Research
August 18, 2022 10:30 ET | Straits Research
New York, United States, Aug. 18, 2022 (GLOBE NEWSWIRE) -- The application of artificial tears protects and hydrates mucous membranes and alleviates dryness and irritation of the eyes. Artificial...
Oyster_Point_RegisteredTM_Logo_RGB.jpg
Oyster Point Pharma Announces TYRVAYA® To Be Covered By the Largest Medicare Pharmacy Benefit Manager
August 17, 2022 08:00 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the...
SightSciences_Logo_2C_RGB.png
Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI® Surgical System in Patients with Open Angle Glaucoma
August 16, 2022 08:01 ET | Sight Sciences, Inc.
MENLO PARK, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to...
ocugen_4C_LOGO (002).png
Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
August 12, 2022 07:30 ET | Ocugen
MALVERN, Pa., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
logo color s and clearside.jpg
Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update
August 09, 2022 07:05 ET | Clearside Biomedical, Inc.
- CLS-AX OASIS Phase 1/2a Trial Data from Cohorts 3 & 4 Expected in November 2022 - - Non-Dilutive Financing Agreement with HealthCare Royalty Supports Progression of CLS-AX Clinical Program - ...
Oyster_Point_RegisteredTM_Logo_RGB.jpg
Oyster Point Pharma To Report Second Quarter 2022 Financial Results On August 11, 2022
August 08, 2022 16:03 ET | Oyster Point Pharma, Inc.
Conference Call and Webcast Scheduled for August 11, 2022, 4:30 p.m. ET PRINCETON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage...
tarsus-logo-stacked-color-532x626.png
Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease
August 05, 2022 08:30 ET | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
logo color s and clearside.jpg
Clearside Biomedical to Participate in Three Upcoming Investor Conferences in August 2022
August 03, 2022 07:05 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
logo color s and clearside.jpg
Clearside Biomedical to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Tuesday, August 9, 2022
July 27, 2022 07:05 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., July 27, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...